Trevi Therapeutics Inc (TRVI) Stock Price, Quote & News

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough i...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 304 2499

Website: www.trevitherapeutics.com

Address:

195 Church Street, 16th Floor, New Haven, United States

Bfunk17 Nov. 14 at 11:49 PM

$TRVI I was looking over at Trevi Institutional Ownership and Fintel is picking up an 11% rise. Obviously, hitting 114+% represents expected shares being Shorted as well. Tutes are incredibly heavy and weighted hear. Also, there used to be 5 long/short combos and thay is down to 4 hedgers. The gist:everyone is really high on Trevi at the moment. Analysts rolled out upgrades all day today. Great investment.

1 · Reply

JarvisFlow Nov. 14 at 8:37 PM

D. Boral Capital has adjusted their stance on Trevi Therapeutics ( $TRVI ), setting the rating to Buy with a target price of 19.

0 · Reply

JarvisFlow Nov. 14 at 5:35 PM

Oppenheimer has adjusted their stance on Trevi Therapeutics ( $TRVI ), setting the rating to Outperform with a target price of 23 → 24.

0 · Reply

JarvisFlow Nov. 14 at 4:58 PM

Morgan Stanley has adjusted their stance on Trevi Therapeutics ( $TRVI ), setting the rating to Overweight with a target price of 18 → 19.

0 · Reply

jlcrane Nov. 14 at 3:28 PM

$TRVI I never understand these selloffs when everything lines up positively. I guess we have to get the tourists out.

1 · Reply

Soheil444 Nov. 14 at 2:04 PM

$TRVI beautiful! lots of price target raises

0 · Reply

Quantumup Nov. 14 at 2:03 PM

Cantor reiterated $TRVI Overweight-$25, and said, This makes TRVI the first and only company to show positive data in both IPF chronic cough and RCC — both hard-to-treat indications with high unmet needs and no approved therapies. $VRNA - $MRK $GSK Cantor added:

0 · Reply

Quantumup Nov. 14 at 12:12 PM

Oppenheimer⬆️ $TRVI to $24 from $23/reit'd at Outperform $MRK $GSK Oppenheimer said: TRVI provided updates across Haduvio's development in chronic cough settings, with the plan to begin the Phase 3 IPF chronic cough program-as well as advance into Phase 2b for refractory chronic cough-in 1H26. Next year should also see the start of a Phase 2 in non-IPF idiopathic lung disease (ILD) chronic cough, an opportunity that may be as large as IPF CC itself. Cash runway anticipated into 2028, and we see meaningful upside as Haduvio's momentum toward commercial builds for a growing group of poorly-served chronic cough indications.

0 · Reply

Quantumup Nov. 14 at 12:11 PM

Clear Street⬆️ $TRVI to $21 from $11/reit'd at Buy $MRK $GSK Clear Street said: We are raising our PT to $21 from $11. The increase reflects an increasingly clear path to P3 for IPF-CC and supporting P1 studies. Additionally, data presented at CHEST 2025 readouts reinforced clinical relevance in both RCC and IPF-CC (details below). Reflecting these data and the regulatory path clarity, we increase RCC PoS to 40% (from 20%) and IPF-CC PoS to 70% (from 50%) in our model.

0 · Reply

Bfunk17 Nov. 14 at 12:06 PM

$TRVI TRVI: Analyst Maintains 'Buy' Rating and Raises Price Target | T https://share.google/wA9NYVbGRuGdoXIoX

0 · Reply

Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 1 day ago

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 4:05 PM EST - 8 days ago

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Nov 4, 2025, 7:30 AM EST - 11 days ago

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Oct 8, 2025, 7:30 AM EDT - 5 weeks ago

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Sep 18, 2025, 7:30 AM EDT - 2 months ago

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Sep 9, 2025, 7:15 PM EDT - 2 months ago

Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:30 AM EDT - 2 months ago

Trevi Therapeutics to Participate in Upcoming September Conferences

Aug 8, 2025, 1:47 PM EDT - 3 months ago

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 4:05 PM EDT - 3 months ago

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 3 months ago

Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 1, 2025, 7:30 AM EDT - 4 months ago

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 5, 2025, 4:30 PM EDT - 5 months ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 3, 2025, 10:15 PM EDT - 5 months ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Jun 2, 2025, 4:01 PM EDT - 5 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Jun 2, 2025, 1:42 PM EDT - 5 months ago

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 1, 2025, 4:00 PM EDT - 5 months ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

May 29, 2025, 7:30 AM EDT - 6 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences

$Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

May 20, 2025, 7:00 AM EDT - 6 months ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 11, 2025, 4:16 AM EDT - 6 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 1, 2025, 4:05 PM EDT - 7 months ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Apr 3, 2025, 7:30 AM EDT - 8 months ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Mar 18, 2025, 6:47 PM EDT - 8 months ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 8 months ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 11, 2025, 4:05 PM EDT - 8 months ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 10, 2025, 11:30 AM EDT - 8 months ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

$Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 10, 2025, 6:00 AM EDT - 8 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

$Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 9, 2025, 4:00 PM EDT - 8 months ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Feb 27, 2025, 7:30 AM EST - 9 months ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 7:30 AM EST - 9 months ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Jan 30, 2025, 7:30 AM EST - 10 months ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 8, 2025, 7:30 AM EST - 11 months ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:36 AM EST - 11 months ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 12, 2024, 9:47 AM EST - 1 year ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 3, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Nov 21, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 11:54 PM EST - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

$Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough$

Oct 21, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Oct 3, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Sep 30, 2024, 5:30 PM EDT - 1 year ago

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Bfunk17 Nov. 14 at 11:49 PM

1 · Reply

JarvisFlow Nov. 14 at 8:37 PM

D. Boral Capital has adjusted their stance on Trevi Therapeutics ( $TRVI ), setting the rating to Buy with a target price of 19.

0 · Reply

JarvisFlow Nov. 14 at 5:35 PM

Oppenheimer has adjusted their stance on Trevi Therapeutics ( $TRVI ), setting the rating to Outperform with a target price of 23 → 24.

0 · Reply

JarvisFlow Nov. 14 at 4:58 PM

Morgan Stanley has adjusted their stance on Trevi Therapeutics ( $TRVI ), setting the rating to Overweight with a target price of 18 → 19.

0 · Reply

jlcrane Nov. 14 at 3:28 PM

$TRVI I never understand these selloffs when everything lines up positively. I guess we have to get the tourists out.

1 · Reply

Soheil444 Nov. 14 at 2:04 PM

$TRVI beautiful! lots of price target raises

0 · Reply

Quantumup Nov. 14 at 2:03 PM

0 · Reply

Quantumup Nov. 14 at 12:12 PM

0 · Reply

Quantumup Nov. 14 at 12:11 PM

0 · Reply

Bfunk17 Nov. 14 at 12:06 PM

$TRVI TRVI: Analyst Maintains 'Buy' Rating and Raises Price Target | T https://share.google/wA9NYVbGRuGdoXIoX

0 · Reply

JarvisFlow Nov. 14 at 11:01 AM

Clear Street has adjusted their stance on Trevi Therapeutics ( $TRVI ), setting the rating to Buy with a target price of 11 → 21.

0 · Reply

Amandawww Nov. 14 at 1:00 AM

$TRVI why file for shelf if buy out soon? Cash until 2028

2 · Reply

Bfunk17 Nov. 13 at 11:58 PM

$TRVI Trevi Therapeutics (TRVI) Advances in Chronic Cough Treatment De https://share.google/EkQZfkHGJz8cJR7ig

0 · Reply

ZR92x Nov. 13 at 11:13 PM

$TRVI Great earnings call. There are really no holes in anything with this company. Cash into 2028. Expenses are very low. Drug-drug interaction study went amazing. EoP2 FDA meeting coming very soon - probably in the next few weeks. I expect potential acquirers to be waiting on confirmation from the FDA at these meetings on the IPF Phase 3 design and non-IPF trial design and then pulling the trigger.

0 · Reply

DARKP00L Nov. 13 at 10:38 PM

$TRVI 17:17 on Nov. 13 2025 Trevi Therapeutics Inc Files For Mixed Shelf; Size Not Disclosed; Says In Addition, Offering Of Up To $200M Of Common Stock #tradeideas

1 · Reply

Bfunk17 Nov. 13 at 9:58 PM

$TRVI Tremendously positive news out of this Q3 report as the safety studies came back all clean. More great trial results as Trevi marches on. With no CFO announced, and a delayed P3 Conversation with the FDA (due Q4...which we are getting late in)...really feels like a BO announcement could come in the next 4 weeks at this point. BPs enjoy being a part of the trial designs and Trevi is right in that pocket right now. It does match up well...but we shall see if this comes through. Looking very positive though. Love this company's momentum right now. HR's on every trial result thus far and they are looking juicy for a BP.

2 · Reply

d_risk Nov. 13 at 9:54 PM

$TRVI - Trevi Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors TRVI’s latest 10-Q risk factors spotlight deeper Haduvio clinical and regulatory plans, mounting cash burn and funding needs, heavy dependence on Haduvio’s success, detailed IP and manufacturing risks, expanded compliance and pricing pressures, and new threats from privacy, cybersecurity, and potential Nasdaq delisting. #Biotechnology #NasdaqListingRisk #Cybersecurity #PricingPressure #Compliance #ManufacturingRisk #IntellectualProperty #FinancialRisk #RegulatoryRisk #ClinicalTrials #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/TRVI/10-Q/2025-11-13

0 · Reply

Bfunk17 Nov. 13 at 3:41 PM

$TRVI Exciting Day. The Q3 readout "should" include: *recent safety trial data *p3 IPF update with FDA *potentially non-IPF FDA update These are important updates as the company closes in on a potential buy-out.

1 · Reply

jlcrane Nov. 13 at 3:16 PM

$TRVI Can we participate, please?

0 · Reply

Drew613 Nov. 12 at 1:48 PM

$TRVI BO soon. Very

1 · Reply

BEATOFtheMARKET Nov. 11 at 9:48 PM

$TRX $TRVI $TRV $TRST $TRP 11/07 11/21

0 · Reply

ZR92x Nov. 11 at 9:46 PM

$TRVI 12.10 close!! Obviously they still think this is undervalued. I was thinking maybe $20-$25 buyout but maybe we could see a $30 buyout now. Bellus was bought for a 103% premium to the previous closing price. Tik tok tik tok… the more they wait the more they pay for golden pharma assets in this XBI bull market.

0 · Reply

Market Cap	1.40B
Revenue (ttm)	0.00
Net Income (ttm)	-47.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,474,100
Avg Vol	2,120,158
Day's Range	N/A - N/A
Shares Out	121.78M
Stochastic %K	56%
Beta	0.67
Analysts	Strong Sell
Price Target	$20.36